Orphazyme stock plummets following bad news from CHMP

The Danish biotech company is being punished on the stock exchange after the CHMP, an EMA expert committee, had a negative reaction to the company’s oral presentation on Wednesday.

Photo: Sydbank/PR

Orphazyme stock is down by 34 percent, dropping to DKK 9.2 (USD 1.4) per share.

On Wednesday night, biotech firm Orphazyme returned from a meeting with the European Medicines Agency’s (EMA) expert committee, the CHMP, which concerned the company’s candidate arimoclomol, a treatment for rare metabolic disease Niemann-Pick type C (NPC).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs